21April

Novo Nordisk A/S - Reduction of the share capital ... Read more

03April

Once-weekly semaglutide demonstrated consistent blood glucose reductions and wei ... Read more

31March

FDA posts briefing materials prior to Advisory Committee meeting for nonacog bet ... Read more

29March

Novo Nordisk resubmits new drug application for fast-acting insulin aspart in th ... Read more

24April

Novo Nordisk A/S - Share repurchase programme ... Read more

21April

Novo Nordisk A/S - Reduction of the share capital ... Read more

10April

Novo Nordisk A/S - Share repurchase programme ... Read more

03April

Novo Nordisk A/S: Status regarding Novo Nordisk's holding of its own shares (31 ... Read more

01April

Silent period,

03May

Financial statement for the first three months of 2017,

04May

Deutsche Bank Annual Healthcare Conference, Boston

10May

Redburn European Equity Conference, Toronto

 

 

 

Investors

 
Share information


Take an advanced view of the Novo Nordisk share

 
Q1 2017 financial results 


Q1 2017 conference call and roadshow presentation

 
Annual Report 2016


Download the Novo Nordisk Annual Report 2016



Novo Nordisk at a glance


Private shareholders


See relevant content for private investors



IR material


Download relevant Investor Relations material



Contacts



Subscriptions


Sign up to receive company announcements.



Q4 2016 financial results


Q4 2016 Conference call and roadshow presentation